The Treatment of Limited Joint Mobility of the Foot in Those with Diabetes

Diabetes mellitus, a chronic metabolic disorder affecting millions worldwide, is associated with numerous complications that extend beyond blood sugar dysregulation. One such underrecognized yet significant issue is limited joint mobility (LJM), also known as diabetic cheiroarthropathy (DCA). This condition primarily manifests in the hands but can profoundly impact the feet, leading to stiffness, reduced range of motion, and heightened vulnerability to secondary problems like ulcers and deformities. In diabetic patients, LJM of the foot arises from long-term hyperglycemia, which promotes the non-enzymatic glycosylation of collagen and other proteins in connective tissues, resulting in thickening and stiffening of the skin, tendons, and joint capsules.

The pathophysiology of LJM in diabetes begins with advanced glycation end-products (AGEs), which accumulate due to persistent high glucose levels. These AGEs cross-link with collagen fibers, impairing their flexibility and leading to periarticular fibrosis. In the feet, this affects joints such as the metatarsophalangeal (MTP) and subtalar joints, as well as the ankle. Risk factors include poor glycemic control, longer duration of diabetes (particularly type 1), and coexisting conditions like neuropathy or peripheral vascular disease. Symptoms in the foot typically include insidious onset of stiffness, making it difficult to dorsiflex the ankle or extend the toes, often described as a "frozen" sensation. Patients may notice challenges with walking, climbing stairs, or wearing certain shoes. Diagnosis is clinical, involving assessments like the "prayer sign" for hands (inability to flatten palms together) and goniometric measurements for foot joint range of motion. In the feet, limited ankle mobility can be quantified by reduced dorsiflexion below 10 degrees. Complications are particularly severe here; LJM increases plantar forefoot pressures, promoting callus formation and ulceration, especially when combined with sensory neuropathy. This "at-risk foot" scenario heightens the likelihood of Charcot neuroarthropathy—a destructive joint condition involving bone fragmentation and deformity—or infections that may necessitate amputation. Moreover, reduced joint adaptability impairs the foot's ability to absorb shock and distribute weight evenly, leading to chronic pain, gait abnormalities, and falls.

Treatment of LJM in the diabetic foot is multifaceted, focusing on symptom relief, mobility restoration, and prevention of complications, as there is no curative therapy beyond addressing the underlying diabetes. The cornerstone is optimizing glycemic control, which halts or slows progression by reducing AGE formation. Guidelines from the American Diabetes Association (ADA) and International Diabetes Federation (IDF) recommend maintaining HbA1c below 7% through lifestyle modifications, oral agents, or insulin therapy. Studies show that intensive glucose management can improve joint flexibility over time, particularly in early-stage LJM. For instance, in type 1 diabetes patients, regular follow-up with endocrinologists to achieve tight control has been linked to reduced DCA severity.

Physical therapy (PT) plays a pivotal role in managing foot-specific LJM. Tailored exercises aim to enhance joint range of motion and strengthen surrounding muscles. Stretching protocols, such as passive dorsiflexion stretches or toe extension maneuvers, are performed daily to counteract stiffness. Hydrotherapy or ultrasound therapy may be incorporated to reduce inflammation and improve tissue elasticity. A randomized study demonstrated that PT interventions, including joint mobilization techniques, significantly lowered plantar pressures and increased ankle mobility in diabetic patients with LJM. Orthotic interventions are equally vital; custom insoles or ankle-foot orthoses (AFOs) redistribute weight, alleviate high-pressure areas, and support joint alignment. The IDF guidelines emphasize offloading devices to prevent ulcers, noting that rocker-bottom shoes can compensate for limited ankle motion by facilitating a smoother gait. In cases of concurrent neuropathy, sensory re-education through PT helps patients adapt to altered proprioception.

Pharmacological options are limited but supportive. Nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen provide symptomatic relief for pain and inflammation associated with joint stiffness. For severe cases, intra-articular corticosteroid injections may be considered, though evidence is anecdotal and risks like infection must be weighed in diabetics. Emerging research explores aldose reductase inhibitors or anti-AGE agents, but these are not yet standard for foot LJM. Pain management may extend to gabapentinoids for neuropathic components, as LJM often coexists with diabetic peripheral neuropathy.

Surgical interventions are reserved for advanced complications rather than LJM itself. Procedures like tendon lengthening (e.g., Achilles tendon release) can restore ankle dorsiflexion in rigid equinus deformities caused by chronic stiffness. For Charcot-related issues stemming from LJM, reconstructive surgery or total contact casting may be employed to stabilize the foot. However, surgery is approached cautiously due to impaired healing in diabetics. The Infectious Diseases Society of America (IDSA) guidelines stress preoperative optimization of vascular status and infection control.

Prevention is integral to treatment paradigms. Regular foot examinations, as per ADA standards, should include joint mobility assessments during annual check-ups. Patient education on self-care—such as daily foot inspections, moisturizing to prevent skin cracking, and avoiding barefoot walking—empowers individuals to mitigate risks. Multidisciplinary teams involving podiatrists, physiotherapists, and diabetologists ensure holistic care. The IWGDF guidelines advocate for risk stratification, classifying LJM-affected feet as high-risk and recommending frequent monitoring.

Treating limited joint mobility in the diabetic foot demands a proactive, integrated approach centered on glycemic optimization, physical therapy, and supportive devices to preserve function and avert complications. While Ljm remains a challenging sequela of diabetes, adherence to established guidelines can significantly improve outcomes. Future research into targeted therapies, such as AGE inhibitors, holds promise for more definitive treatments. Ultimately, early intervention and patient engagement are key to transforming this condition from a debilitating threat into a manageable aspect of diabetes care.

Craig Payne is a University lecturer, runner, cynic, researcher, skeptic, forum admin, woo basher, clinician, rabble-rouser, blogger and a dad.